Anti-Rheumatic Drugs - Colombia

Colombia

in Colombia, a country known for its rich history and cultural heritage, is also making significant strides in the pharmaceutical industry.
In the realm of Anti-Rheumatic Drugs market, in Colombia is projected to witness a noteworthy revenue growth.
By the year 2024, the revenue in this market is estimated to reach a staggering €48.89m.
This positive trend is expected to continue, with an annual growth rate (CAGR 2024-2029) of 0.63%.
As a result, the market volume is anticipated to reach €50.45m by 2029.
While in Colombia is poised for growth, it is essential to put these figures into a global context.
When compared to other countries, United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market.
In 2024, United States is projected to reach an impressive revenue of €31,850.00m.
This showcases the dominance of the US market in this particular pharmaceutical market.
Colombia's demand for anti-rheumatic drugs is on the rise, driven by an increasing prevalence of rheumatoid arthritis in the country.

Key regions: Germany, United States, India, Japan, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Rheumatic Drugs market in Colombia has been witnessing significant growth in recent years.

Customer preferences: Colombian customers are showing a growing demand for Anti-Rheumatic Drugs due to the increasing prevalence of rheumatic diseases in the country. The aging population and changing lifestyle patterns are some of the factors contributing to the rise in the incidence of rheumatic diseases.

Trends in the market: The Anti-Rheumatic Drugs market in Colombia is witnessing a shift towards biologic drugs. Biologic drugs have gained popularity due to their high efficacy and fewer side effects compared to traditional drugs. The market is also witnessing the entry of new players, which is intensifying the competition in the market and leading to the launch of new products.

Local special circumstances: Colombia has a well-established pharmaceutical industry, which is driving the growth of the Anti-Rheumatic Drugs market. The government has also taken initiatives to improve access to healthcare and reduce the burden of rheumatic diseases, which is expected to further boost the demand for Anti-Rheumatic Drugs in the country.

Underlying macroeconomic factors: The Colombian economy has been growing steadily in recent years, which is contributing to the growth of the Anti-Rheumatic Drugs market. The government's efforts to improve the regulatory environment and attract foreign investments are also expected to drive the growth of the pharmaceutical industry in the country. However, the market is also facing challenges such as the high cost of biologic drugs and the lack of awareness among patients about the availability of effective treatments.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.